Suzhou Redgia Biotech

Regor Therapeutics is a clinical-stage biotechnology company headquartered in Suzhou, China, with additional operations in Shanghai and Boston. The company utilizes its proprietary Computer Accelerated Rational Discovery (CARD) platform to design and develop high-quality small molecule therapeutics for metabolic diseases, oncology, and autoimmune disorders. Regor's CARD platform integrates structural biology, computational chemistry, and medicinal chemistry to efficiently tackle challenging biological targets. The company's lead clinical program, RGT-075, is an oral small molecule GLP-1 receptor agonist being evaluated for the treatment of type 2 diabetes and obesity. In 2021, Regor entered into a significant strategic collaboration with Eli Lilly and Company, valued at up to $1.5 billion, to discover and develop novel therapies for metabolic disorders. The company is backed by prominent investors including Qiming Venture Partners and Lilly Asia Ventures.